White House reviews plan to let pharmacies compound restricted peptides
An interim access policy from Health and Human Services would give compounding pharmacies temporary room to make selected peptides without immediate enforcement action. FDA scientists say human evidence on safety and effectiveness is insufficient.
2 min read